Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression and correlation with survival status in HNSC. (a) SLC2A3 mRNA expression levels in pan-cancer data from TCGA. (b) Comparison of SLC2A3 mRNA expression levels between all normal tissues and HNSC samples from TCGA. (c) SLC2A3 mRNA expression in matched HNSC samples from TCGA. (d) the relationship between SLC2A3 mRNA expression and tumor stages of HNSC patients in the UALCAN database. The correlation between SLC2A3 expression and (e) disease-specific survival, (f) overall survival (OS) in TCGA and (G) OS in GSE65858. (h) ROC curve analysis of SLC2A3 diagnosis. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Comparison, Biomarker Discovery

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was associated with the clinicopathological features of HNSC based on TCGA. (a) Univariate and (b) multivariate Cox analyses of SLC2A3 expression and clinicopathological variables. Kaplan – Meier analysis of overall survival for patients showed significant differences between high and low SLC2A3 expression groups with (c) T stage (d), N stage (e), M stage and (f) clinical stages.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: Enrichment analysis of the SLC2A3 gene coexpression network in HNSC. Heatmaps show the top 50 coexpressed genes (a) positively and (b) negatively correlated with SLC2A3 expression in HNSC. Enrichment analysis of (c) KEGG and (d – f) GO for SLC2A3 coexpression genes.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was correlated with EMT gene signatures in TCGA-HNSC. GSEA of DEGs between the low and high SLC2A3 expression groups from TCGA-HNSC for (a) activated pathways and (b) EMT gene signature. NES: normalized enrichment score. FDR: false discovery rate. (c-j) Correlation between SLC2A3 expression and EMT-related genes.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was associated with NF-κB, and NF-κB was associated with EMT gene signatures in TCGA-HNSC. (a) GSEA of DEGs between the low and high SLC2A3 expression groups from TCGA-HNSC for NF-κB signaling. NES: normalized enrichment score. FDR: false discovery rate. (b) Correlation between SLC2A3 and the expression of NF-κB1, NF-κB2, REL, RELA and RELB. (c) Both RELB and NF-κB2 were positively correlated with the expression of N-cad, vimentin, Snai1 and MMP9 and negatively correlated with the expression of E-cad.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was correlated with IL6/JAK/STAT3 signaling and interferon-γ hallmark gene sets. GSEA of DEGs between the low and high SLC2A3 expression groups from TCGA-HNSC for the (a) IL6/JAK/STAT3 signaling pathway and (b) interferon- γ response pathway. NES: normalized enrichment score. FDR: false discovery rate. (c-g) the positive correlation between SLC2A3 and the expression of CXCR4, CCR1, CCR, CCL2 and CCL13 based on TCGA-HNSC. (h) SLC2A3 knockdown inhibited the mRNA expression of CXCR4, CCR1, CCR8, CCL2, and CCL13. Each value represents the mean ± SD of three separate experiments. *P < 0.05; **P < 0.01.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Knockdown

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: Correlation between SLC2A3 expression and tumor immune infiltrating cells. (a) Infiltration of 22 immune infiltrating cells between HNSC patients with low and high SLC2A3 expression obtained by CIBERSORTx. (b) Comparison of immune infiltrating cell levels in HNSC with different SLC2A3 CNVs. (c) Clinical survival outcome of HNSC patients with high B cell, CD8+ T-cell and myeloid dendritic cell infiltration. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Comparison

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: Scatter plot of the relationship between SLC2A3 expression and drug sensitivity. SLC2A3 expression was (a, b, d-h, j-l) negatively or (c, i) positively correlated with the IC50 of drugs approved by the FDA. (M) Effect of obatoclax and triciribine on cell viability upon SLC2A3 knockdown. *P < 0.05.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Knockdown

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 knockdown inhibited proliferation and migration and NF-κB/EMT-related gene expression in FaDu and CNE-2 cell lines. (a) SLC2A3 mRNA expression in adjacent normal tissues (ANT) and HNSC samples. (b) Cell proliferation and (c) migration were suppressed upon SLC2A3 knockdown. (d) SLC2A3 knockdown inhibited N-cad, Vimentin, and Snai1 expression but increased E-cad expression. (e) NF-κB P65 expression was decreased upon SLC2A3 knockdown. Each value represents the mean ± SD of three separate experiments. * p < 0.05, # p < 0.01.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Knockdown, Migration, Gene Expression, Expressing

Journal: The Journal of Neuroscience

Article Title: Structural and Functional Rescue of Chronic Metabolically Stressed Optic Nerves through Respiration

doi: 10.1523/jneurosci.3652-17.2018

Figure Lengend Snippet: Figure 1. Glycogen and glial glucose transporters decreased with glaucoma pathology. 905 A, Glycogen analysis in 3, 6, and 10-month DBA/2J (D2) and control DBA/2J-Gpnmb+ (D2G) optic nerve (ON), 906 (n=6 ON per group). B and F, Capillary electrophoresis of GLUT1 B, and GLUT3 F, protein in 3, 6, and 10-month 907 D2 and D2G ON normalized to total protein then to 3m D2G protein levels (n=8 ON per group). See Figure 1-1. 908 C, Distribution of GLUT1 in ON of 3m D2, and 10m D2G and D2 optic nerves immunolabeled with GFAP 909 (green). Arrows indicate colocalization of GLUT1 and GFAP, (n=3 sections per ON, 6 ON per group). D and E, 910 Glut1 and Glut3 mRNA levels in 3, 6, and 10-month D2 and D2G ON, normalized to Hprt mRNA then to 3m 911 D2G mRNA (n=5-7 ON per group). See Figure 1-1. G, Distribution of GLUT3 in ON stained with Fluoromyelin. 912 Arrows indicate colocalization of GLUT3 with Fluoromyelin, (n=3 sections per ON, 6 ON per group). H and I, 913 Percent of mean fluorescence intensity in the region of interest (ROI) for C, GLUT1 and G, GLUT3. All values are 914 presented as mean ± SEM, one-way ANOVA and Tukey’s post-hoc test. A, F(5, 30) =18.59, **p = 0.0022, ***p 915 = 0.00011; B, F(5, 42) = 6.463, **p = 0.0077; D, F(5, 30) = 1.906, **p = 0.001; E, F(5, 37) = 15.58, **p= 0.0023, 916 ***p =0.0001; H, F(2, 51) = 210.4, ***p = 0.0001. Scale bar=20μm for C and G. 917 918 Figure 2. Monocarboxylate transporters downregulated with glaucoma pathology. 919 A, Mct1 mRNA levels in 3, 6, and 10-month D2 and D2G ON, normalized to Hprt mRNA then to 3m D2G mRNA 920 (n=5-13 ON per group). See Figure 2-1. B, D and E, MCT1, MCT2 and MCT4 protein levels in 3, 6 and 10-month 921 D2G and D2 ON, normalized to total protein and then to 3m D2G protein levels (n=8 ON per group). C, F and G, 922 Distribution of MCT1 C, MCT2 F, and MCT4 G, in 3m D2, and 10m D2G and D2 ON stained with Fluoromyelin 923 (green) or immunolabeled with GFAP (green). Arrows indicate colocalization (n=3 sections per ON, 6 ON per 924 group). H, Distribution of MCT2 in human control and glaucoma patient ON, immunolabeled for β-tubulin 925 (green) and stained with DAPI (blue). Arrows indicate colocalization (n=4 sections per ON, 2 ON per group). 926 See Figure 2-1. I-L, Percent of mean fluorescence intensity in the ROI for I, MCT1, J, MCT2, K, MCT4 D2 and 927 D2G ON, and L MCT2, human ON. M, Quantification of total number of RGC axons in 6m D2, 10m D2G and 928 10m D2 ON. All values are presented as mean ± SEM, one-way ANOVA and Tukey’s post-hoc test. A, F(5, 47) = 929 4.579, *p = 0.0141; B, F(5, 38) = 6.553, **p = 0.0076; D, F(5, 42) = 16.14, *p = 0.0054, **p = 0.0013; E, F(5, 42) 930 = 4.734, *p= 0.0348; I, F(2, 51) = 173.2, ***p = 0.0001; J, F(2, 51) = 402.1, ***p = 0.0001; K, F(2, 51) = 192.6, 931 ***p = 0.0001; L, t(6) = 9.317, ***p = 0.0001, two-tailed unpaired t-test). Scale bar=20μm applies to C, F, G, 932 and H. 933 934 935 Figure 3. Low lactate accompanies AMPK activation and limits mitochondrial biogenesis and metabolic 936 cofactor pools. 937 A, L-lactate levels in 3, 6 and 10-month D2G and D2 ON (n=8 ON per group). B, Ratio of phosphorylated-AMPK 938 (pAMPK) to AMPK protein in 3, 6 and 10-month D2G and D2 ON (n=8 ON per group). C-D, Phosphorylated 939 AMPK immunofluorescence (magenta) and GFAP (green) micrographs in C, human control and glaucoma ON 940 (n=4 sections per ON, 2 ON per group); and D, 3m D2, and 10m D2G and D2 mice (n= 3 sections per ON, 6 ON 941 per group). Arrows indicate colocalization of pAMPK and GFAP. E-F, Percent of mean fluorescence intensity in 942 the region of interest (ROI) for pAMPK in E, 3m D2, and 10m D2G and D2 mice, and F, human. G-I, Analyses of 943 NAD+/NADH, creatine kinase (CK) activity and PGC1-α levels in 3, 6 and 10-month D2G and D2 mice. G, NAD+ 944 normalized to NADH levels (n=6 ON per group). See Figure 3-1. H, Creatine kinase activity normalized to total 945 protein (n=6 ON per group). I, PGC1-α protein levels normalized to total protein levels and then to 3m D2G 946 protein levels (n=8 ON per group). All values are presented as mean ± SEM, one-way ANOVA and Tukey’s post- 947 hoc test. A, F(5, 42) = 22.04, *p = 0.0124; B, F(5, 42) = 35.51, **p = 0.0032, ***p = 0.0001; E, F(2, 45) = 208.4, 948

Article Snippet: List of antibodies used for IHC and Capillary Electrophoresis analyses 1103 Antibody Dilution RRID Company Host AKT1 1:50 for WES AB_329827 Cell Signaling Technology Rabbit AMPK α1 2B7 1:200 for WES AB_2721834 Novus Biologicals Mouse BDNF 1:100 for IHC AB_630940 Santa Cruz Biotechnology Rabbit Brn3a 1:50 for IHC AB_626765 Santa Cruz Biotechnology Mouse βIII-tubulin 1:1000 for IHC AB_107216 Abcam Chicken GLUT1 1:200 for IHC, 1:50 for WES AB_790014 Novus Biologicals Rabbit GLUT3 1:25 for IHC and WES AB_2191306 R&D Systems Mouse Glutamine Synthetase 1:50 for WES AB_1127501 Santa Cruz Biotechnology Mouse GFAP 1:250 for IHC AB_10917109 EMD Millipore Mouse GFAP 1:500 for IHC AB_10013382 Dako-Agilent Rabbit MCT1 1:25 for IHC and WES AB_10841766 Santa Cruz Biotechnology Mouse MCT2 1:50 for WES AB_2721836 Aviva Systems Biology Rabbit 1:50 for WES AB_10855300 Bioss Rabbit MCT4 1:250 for IHC AB_2254765 Santa Cruz Biotechnology Goat 1:50 for WES AB_2189333 Santa Cruz Biotechnology Rabbit NRF2 1:25 for IHC AB_2618882 Developmental Studies Hybridoma Bank Mouse RBPMS 1:200 for IHC AB_10720427 GeneTex Inc. Rabbit PhosphoAKTSer 473 1:50 for WES AB_329825 Cell Signaling Technology Rabbit pAMPK α1Thr 172 1:100 for IHC, 1:50 for WES AB_11032916 Novus Biologicals Rabbit p70S6K 1:50 for WES AB_331676 Cell Signaling Technology Rabbit Phosphop70S6KThr 389 1:50 for WES AB_330944 Cell Signaling Technology Rabbit Phosphop70S6KSer 411 1:25 for WES AB_2182257 Santa Cruz Biotechnology Mouse SOD2 1:100 for IHC AB_2191814 Santa Cruz Biotechnology Mouse TFAM 1:50 for IHC AB_10610743 Santa Cruz Biotechnology Mouse 1104 48 48 1105 Table 2.

Techniques: Control, Electrophoresis, Immunolabeling, Staining, Fluorescence, Two Tailed Test, Activation Assay, Immunofluorescence, Activity Assay

Journal: bioRxiv

Article Title: Endocrine-metabolic decoupling drives stress vulnerability in dystrophin deficiency

doi: 10.64898/2026.02.22.707291

Figure Lengend Snippet: a , Area under the curve (AUC) for blood glucose concentrations following a 5-h fast and intraperitoneal injection of insulin (0.5 IU kg⁻¹; insulin tolerance test (ITT)) measured at rest (non-stressed) or during a 2-h tube-restraint (stressed). b , Relative frequency distribution of pancreatic islet area from isolated islets. c , Mean pancreatic islet area. d-f , Representative immunoblot (d) and quantification of glucose transporter 3 (GLUT3) protein abundance in triceps (e) and brain (f) extracts, normalised to total protein and expressed relative to WT. g , [¹⁸F] fluorodeoxyglucose (¹⁸F-FDG) standardised uptake values (SUV) in templated brain regions from mice treated with exogeneous insulin prior to stress or non-stress conditions. Data were analysed using repeated-measures ANOVA or linear mixed-effects models with Bonferroni post-hoc adjustments, or One-way ANOVA or Kruskal-Wallis with Dunn’s post-hoc testing. n =6-8 per group. Data are mean ± SEM. * P < 0.05.

Article Snippet: After blocking in 5% BSA or skim milk in TBST for 1 h, membranes were incubated overnight at 4°C with primary antibodies for GLUT3 (ProteinTech, 1:500) or GLUT4 (Thermo Fisher, 1:500).

Techniques: Injection, Isolation, Western Blot, Quantitative Proteomics